Core Viewpoint - The China Securities Index announced temporary adjustments to the sample stocks of the CSI 1000, CSI 500, and CSI A500 indices, effective after the market close on January 9, 2026 [1] Group 1: Index Adjustments - Chipone Technology is added to the CSI 500 index [1] - Mingyue Optical is added to the CSI 1000 index [1] - BGI Genomics is added to the CSI A500 index [1] Group 2: Exclusions from Indices - ST Renfu is removed from both the CSI 500 and CSI A500 indices [1] - Chipone Technology is removed from the CSI 1000 index [1]

（文章来源：每日经济新闻） 每经AI快讯，1月6日，中证指数今日发布公告，根据指数临时调样规则及编制方案，中证指数有限公 司决定调整中证1000、中证500和中证A500指数样本，于2026年1月9日收市后生效。据名单显示，芯源 微调入中证500指数，明月镜片调入中证1000指数，华大智造调入中证A500指数；ST人福调出中证500 及中证A500指数，芯源微调出中证1000指数。 ...

Core Viewpoint - The announcement by China Securities Index Co., Ltd. on January 6 indicates adjustments to the sample stocks of the CSI 1000, CSI 500, and CSI A500 indices, effective after market close on January 9, 2026 [1] Group 1: Index Adjustments - Chipone Technology is added to the CSI 500 index [1] - Mingyue Lens is added to the CSI 1000 index [1] - BGI Genomics is added to the CSI A500 index [1] Group 2: Exclusions from Indices - ST Renfu is removed from both the CSI 500 and CSI A500 indices [1] - Chipone Technology is removed from the CSI 1000 index [1]

Group 1 - The core viewpoint is that brain-computer interfaces (BCIs) are becoming a key part of China's 14th Five-Year Plan, with strong policy support expected to accelerate industry implementation, presenting significant investment opportunities [1] - BCIs represent both medical and technological investments, with short-term applications focused on disease treatment and long-term potential to integrate with AI and robotics, potentially opening up a trillion-dollar market [1] - The report emphasizes the importance of identifying "true brain machines" that align with national policy support and real demand, highlighting China's relative global leadership in BCI technology research [1] Group 2 - From a global perspective, China's pharmaceutical industry is characterized by "innovation upgrades and supply chain resilience," with significant overseas licensing of innovative drugs expected to surpass last year's total by Q3 2025 [2] - The report outlines a focus on high-quality development in the domestic market, emphasizing policy initiatives such as procurement optimization and diversified payment systems, alongside the commercialization of innovative drugs and the safety of supply chains [3] - The report suggests that the Chinese pharmaceutical industry is gradually gaining global competitiveness, with a long-term outlook for the industry to produce large global companies, particularly in innovative drugs and medical devices [5] Group 3 - The investment outlook for 2026 remains positive, with expectations of improved global liquidity favoring the pricing of innovative assets and government policies encouraging industry innovation [5] - Key sectors to watch include innovative drugs and medical devices, with specific companies highlighted such as Heng Rui Medicine, Innovent Biologics, and Mindray Medical [5] - The report indicates a need for investors to be aware of the challenges associated with international expansion, emphasizing the importance of assessing the international competitiveness of companies' products and teams [5]

Group 1 - The core viewpoint of the articles highlights the significant market optimism surrounding the brain-computer interface (BCI) industry, driven by technological advancements and policy support, particularly following Neuralink's announcement of large-scale production by 2026 [1][2] - The Shanghai Composite Index rose by 0.6%, the Shenzhen Component Index by 0.71%, and the ChiNext Index by 0.48%, indicating a positive market sentiment [1] - The Shanghai Stock Exchange Science and Technology Innovation Board Biomedicine Index (000683) increased by 1.1%, with notable gains from companies such as Xiangyu Medical, Huada Zhizao, and Yuekang Pharmaceutical [1] Group 2 - The BCI industry is experiencing a high growth phase, supported by multiple factors including technological breakthroughs and the expectation of human-machine ecosystem collaboration [2] - The Science and Technology Innovation Biomedicine ETF (588250) rose by 1.13%, with a trading volume of 2.0948 million yuan, reflecting investor interest in BCI-related stocks [2] - The ETF tracks the performance of 50 major companies in the biomedicine sector listed on the Science and Technology Innovation Board, indicating a focus on the overall performance of the biomedicine industry [2]

Core Viewpoint - The article provides an objective ranking of open-end fund net values, highlighting the top-performing and underperforming funds based on their recent net value changes [1]. Fund Performance Summary Top 10 Funds by Net Value Growth - The top-performing funds over the past five days include: 1. Huayin Health Life Theme Flexible Allocation: 1.2860, +11.83% 2. Bank of China Health Life Mixed: 2.6160, +10.33% 3. Founder Fubon Core Advantage Mixed A: 1.2438, +10.02% 4. Founder Fubon Core Advantage Mixed C: 1.2276, +10.01% 5. Yongying Pioneer Semiconductor Intelligent Selection Mixed A: 1.4573, +9.27% 6. Yongying Pioneer Semiconductor Intelligent Selection Mixed C: 1.4548, +9.26% 7. Great Wall Consumption Value Mixed A: 1.2019, +8.66% 8. Great Wall Consumption Value Mixed C: 1.1853, +8.64% 9. Dongfang Alpha Technology Intelligent Selection Mixed A: 1.1577, +8.44% 10. Dongfang Alpha Technology Intelligent Selection Mixed C: 1.1568, +8.44% [2]. Bottom 10 Funds by Net Value Growth - The underperforming funds over the past five days include: 1. Huabao Overseas New Energy Vehicle Stock Initiation A: 1.7237, -1.63% 2. Huabao Overseas New Energy Vehicle Stock Initiation C: 1.7070, -1.63% 3. Morgan China Century Mixed (QDII) RMB: 1.9771, -1.48% 4. Tianhong Global High-end Manufacturing Mixed C: 1.8463, -1.46% 5. Tianhong Global High-end Manufacturing Mixed A: 1.8609, -1.46% 6. Chuangjin Hexin Global Pharmaceutical Biotechnology Stock Initiation C: 1.7003, -1.39% 7. Chuangjin Hexin Global Pharmaceutical Biotechnology Stock Initiation A: 1.7162, -1.38% 8. Invesco Great Wall Global Semiconductor Chip Stock A (QDII-LOF): 1.9794, -1.25% 9. Invesco Great Wall Global Semiconductor Chip Stock C (QDII-LOF): 1.9565, -1.25% 10. Jiashi Global Industry Upgrade Stock Initiation C: 2.5437, -1.23% [3][4]. Market Analysis - The Shanghai Composite Index opened high and showed a strong upward trend, closing with a significant increase. The total trading volume reached 2.56 trillion, with a market breadth of 4185 gainers to 1169 losers. The leading sectors included insurance, healthcare, internet, and semiconductors, all rising over 4% [6]. - Notable concepts that surged included brain engineering, blood oxygen monitors, and cloud gaming, each increasing over 5%. Conversely, the sectors that lagged included oil, hotel and catering, and public transportation [6]. Fund Holdings and Concentration Huayin Health Life Theme Fund - The fund has a high concentration of holdings at 60.58%, with significant positions in: 1. United Imaging Healthcare: 5.81% 2. Yirui Technology: 6.51% 3. Mindray Medical: 4.80% 4. BGI Genomics: 5.09% 5. MicroPort Scientific: 8.77% 6. Tianzhihang: 10.66% 7. Other notable holdings include Kai Li Medical and Weicheng Medical, both showing substantial growth [8]. Huabao Overseas New Energy Vehicle Fund - This fund has a higher concentration of 75.42%, with major holdings in: 1. NIO Inc.: 9.89% 2. NVIDIA Corporation: 9.71% 3. Ferrari: 9.23% 4. Tesla Inc.: 8.34% 5. Broadcom Inc.: 7.98% 6. Other significant positions include Carvana and Pony.ai, with notable fluctuations in value [8].

Group 1 - The core viewpoint of the news is that BGI Genomics has seen a stock price increase of 5.13%, reaching 63.88 CNY per share, with a total market capitalization of 26.607 billion CNY as of the report date [1] - BGI Genomics, established on April 13, 2016, and listed on September 9, 2022, focuses on the life sciences and biotechnology sectors, with 90.89% of its revenue coming from the sales of instruments, reagents, and consumables [1] - The company has a revenue composition of 90.89% from sales of instruments and consumables, 7.10% from services, and 2.01% from other sources [1] Group 2 - From the perspective of fund holdings, Guolian Fund has a significant position in BGI Genomics, with its Guolian Medical Health Mixed A fund holding 40,500 shares, representing 9.25% of the fund's net value [2] - The Guolian Medical Health Mixed A fund has a total scale of 8.3061 million CNY and has achieved a year-to-date return of 11.44%, ranking 5616 out of 8155 in its category [2] - The fund has a cumulative return of 25.67% since its inception on September 19, 2018 [2] Group 3 - The fund manager of Guolian Medical Health Mixed A is Liu Baichuan, who has been in the position for 345 days, managing assets totaling 30.2729 million CNY [3] - During Liu Baichuan's tenure, the best fund return was 14.38%, while the worst was 14.12% [3]

财通资管创新医药混合A（019740）基金经理为王鑫园。 截至发稿，王鑫园累计任职时间57天，现任基金资产总规模3.59亿元，任职期间最佳基金回报-6.35%， 任职期间最差基金回报-9.67%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 从基金十大重仓股角度 数据显示，财通证券资管旗下1只基金重仓华大智造。财通资管创新医药混合A（019740）三季度持有 股数4.5万股，占基金净值比例为8.62%，位居第六大重仓股。根据测算，今日浮盈赚取约14.04万元。 财通资管创新医药混合A（019740）成立日期2024年1月23日，最新规模641.63万。今年以来收益 42.96%，同类排名1719/8155；近一年收益42.96%，同类排名1719/8155；成立以来收益39.66%。 1月5日，华大智造涨5.13%，截至发稿，报63.88元/股，成交2.83亿元，换手率1.10%，总市值266.07亿 元。 资料显示，深圳华大智造科技股份有限公司位 ...

12月31日，华大智造涨0.07%，成交额9699.25万元。两融数据显示，当日华大智造获融资买入额730.15 万元，融资偿还813.60万元，融资净买入-83.46万元。截至12月31日，华大智造融资融券余额合计3.98 亿元。 分红方面，华大智造A股上市后累计派现1.50亿元。 机构持仓方面，截止2025年9月30日，华大智造十大流通股东中，易方达上证科创板50ETF（588080） 位居第七大流通股东，持股752.58万股，相比上期减少109.79万股。华夏上证科创板50成份ETF （588000）位居第八大流通股东，持股734.95万股，相比上期减少418.28万股。华宝中证医疗ETF （512170）位居第十大流通股东，持股581.97万股，相比上期减少122.02万股。南方中证500ETF （510500）、香港中央结算有限公司退出十大流通股东之列。 责任编辑：小浪快报 融资方面，华大智造当日融资买入730.15万元。当前融资余额3.92亿元，占流通市值的1.56%，融资余 额超过近一年60%分位水平，处于较高位。 融券方面，华大智造12月31日融券偿还2600.00股，融券卖出4300.00股 ...

Summary of Key Points from Conference Call Records Industry Overview - The high-value consumables market in China has reached a bottom, with international markets showing growth potential. Companies with internationalization capabilities in high-value consumables are seen as having investment potential, especially under the influence of centralized procurement policies accelerating domestic substitution [1][2]. - The commercial model of high-value consumables is advantageous, with stable pricing that is not easily iterated. After the completion of centralized procurement in the Chinese market, combined with overseas R&D progress, the high-value consumables sector is expected to present investment opportunities. The market capitalization of innovative consumables companies in Hong Kong is currently low, with expectations for improved profitability post-2026 [1][2]. Core Insights and Arguments - By 2025, the domestic high-value consumables industry is expected to mature with stable pricing due to centralized procurement. Some products are undergoing clinical trials in Europe and the U.S., indicating potential for overseas market entry or partnerships [2]. - The valuation of the global medical consumables market is high, particularly for leading companies. The pricing of high-value consumables in the U.S. is approximately double that in China, indicating lower elasticity compared to innovative drugs [2]. - The total market capitalization of 15 leading innovative consumables companies in Hong Kong is estimated at around 70-80 billion HKD, which is considered low. It is anticipated that by 2026, around 60% of consumables will be included in centralized procurement [2][8]. Internationalization Progress - Several domestic high-value consumables companies have made significant strides in internationalization. For instance, products from companies like Times Angel and MicroPort are seeing rapid sales growth overseas, particularly in non-European and American markets [3]. - To enter the European and American markets, clinical trials and local approvals are necessary. Collaborations, such as that between Edwards and Jianxi Medical, highlight the growing recognition of Chinese companies' R&D capabilities [3]. Advantages and Catalysts in High-Value Consumables - The domestic high-value consumables sector benefits from low clinical costs and high surgical volumes, which facilitate product improvements. Chinese companies can conduct R&D and production at lower costs, enhancing competitiveness [4]. - Key catalysts to watch include: 1. MicroPort's Firehawk heart stent, expected to receive FDA approval in 2026. 2. Jianxi Technology's tricuspid valve treatment device, anticipated to gain European approval in 2026 while seeking global business development partners [4]. Financial Performance and Industry Impact - The innovative device sector reported positive profits in the first half of 2025, with MicroPort playing a crucial role. It is expected that MicroPort will achieve profitability by 2026 through operational and debt control, positively impacting the entire sector [6]. - The FDA breakthrough certifications for domestic medical devices have become significant barriers for international collaboration, attracting more investment and attention [5]. Impact of Centralized Procurement Policies - Centralized procurement policies have led to an import substitution effect, increasing the market share of domestic products. By 2026, it is projected that about 60% of consumables will fall under centralized procurement, with orthopedic products already reaching 90% [8]. - Companies in the neuro-interventional field, such as Guichuang Tongqiao, are expected to benefit significantly from these policies [8]. Comparison with Innovative Drugs - The development paths of domestic innovative drugs and high-value consumables differ, with both sectors actively exploring international markets. Future focus areas include neuro-interventional, valve, and PFA high-value consumables [9]. Investment Selection Criteria - When selecting investment targets, factors such as surgical volume growth, foreign capital share, centralized procurement expectations, and internationalization potential should be considered. Companies like Guichuang Tongqiao and Peijia in the neuro-interventional field are highlighted as worthy of attention [10]. Insights from U.S. NGS Industry - The U.S. NGS (Next-Generation Sequencing) industry is experiencing strong growth, with companies like Grell and Garden exceeding sales expectations. This sector's development may provide valuable insights for the domestic market [11].